Sanofi (France) Dengue Bid Seen as $2.6 Billion Hit or $800 Million Flop

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Sanofi (SAN), whose vaccines have all but eradicated polio, recently flew journalists from around the globe to a sparkling new factory in France to tout its next big project -- the world’s first vaccine for dengue. That takes confidence, considering mid-stage studies for the shot last year yielded results that ranged from perplexing to disappointing. Sanofi is forging ahead. It’s readying commercial production of a vaccine to prevent the debilitating and sometimes fatal mosquito-borne malady that’s had outbreaks in the U.S. and Europe and threatens half the global population.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC